Collectively, these data support the development of a combination of ZGGS15 plus anti-PD-1 mAb as a promising therapeutic strategy in clinical oncology that has the potential to enhance anti-tumor responses in more cancer types compared with anti-PD-1 mAb monotherapy. This evidence concerns the gene PDCD1 and neoplasm.